Glaxo closing in on two major drug deals

 

• Capping a spate of recent deals worth £100M ($135M), GlaxoSmithKline (NYSE:GSK) is set to ink two major drug deals this week on either side of the Atlantic, The Mail on Sunday reports.
• The potential targets include a US biotech developing treatments for neurological disorders and a UK firm with a promising early-stage treatment for immune disorders affecting millions globally.
• With shares losing more than a fifth in value during the year, the company appears to have lost out to frontrunners in the COVID-19 vaccine race, underperforming Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX), and AstraZeneca (NASDAQ:AZN).
• This month, GSK and its partner in COVID-19 vaccine development, Sanofi (NASDAQ:SNY) were forced to delay their program when Phase 1/2 interim results showed an insufficient immune response in people over 60.
• https://seekingalpha.com/news/3646028-gsk-is-closing-in-on-two-major-drug-deals-report